BAP1-related signature predicts benefits from immunotherapy over VEGFR/mTOR inhibitors in ccRCC: a retrospective analysis of JAVELIN Renal 101 and checkmate-009/010/025 trials
Cancer Immunology, Immunotherapy · 2023
DOI: 10.1007/s00262-023-03424-4 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Immunology, Immunotherapy, 2023. Verfasst von Kan Liu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, The Third Medical Center of PLA General Hospital, Yongding Road 69, Haidian District, Beijing, 100039, China. Hauptthemen laut MEDLINE: Carcinoma, Renal Cell, Antineoplastic Agents, Kidney Neoplasms. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 75 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: National Natural Science Foundation of China, Hainan Province Science and Technology Special Fund.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, The Third Medical Center of PLA General Hospital, Yongding Road 69, Haidian District, Beijing, 100039, China.
- Burning Rock Biotech, Guangzhou, Guangdong, China.
- Department of Urology, The Third Medical Center of PLA General Hospital, Yongding Road 69, Haidian District, Beijing, 100039, China. xzhang301@163.com.
- Department of Urology, The Third Medical Center of PLA General Hospital, Yongding Road 69, Haidian District, Beijing, 100039, China. stopping3721@foxmail.com.
Förderung
- National Natural Science Foundation of China
- Hainan Province Science and Technology Special Fund
Zitieren
APA
Liu, K., Huang, Y., Xu, Y., Wang, G., Cai, S., Zhang, X., & Shi, T. (2023). BAP1-related signature predicts benefits from immunotherapy over VEGFR/mTOR inhibitors in ccRCC: a retrospective analysis of JAVELIN Renal 101 and checkmate-009/010/025 trials. Cancer Immunology, Immunotherapy. https://doi.org/10.1007/s00262-023-03424-4
Vancouver
Liu K, Huang Y, Xu Y, Wang G, Cai S, Zhang X, et al. BAP1-related signature predicts benefits from immunotherapy over VEGFR/mTOR inhibitors in ccRCC: a retrospective analysis of JAVELIN Renal 101 and checkmate-009/010/025 trials. Cancer Immunology, Immunotherapy. 2023. doi:10.1007/s00262-023-03424-4
BibTeX
@article{Liu2023,
author = {Liu, Kan and Huang, Yan and Xu, Yu and Wang, Guoqiang and Cai, Shangli and Zhang, Xu and Shi, Taoping},
title = {BAP1-related signature predicts benefits from immunotherapy over VEGFR/mTOR inhibitors in ccRCC: a retrospective analysis of JAVELIN Renal 101 and checkmate-009/010/025 trials},
journal = {Cancer Immunology, Immunotherapy},
year = {2023},
doi = {10.1007/s00262-023-03424-4}
}
EUVIMED